Oncolytics Biotech (ONCY): SEC Form 3 filed by new insider Mcadory John Bearden
Stocks in this Quantisnow insightHealth Care
Historical context for ONCY
Across the 25 sessions after earlier ONCY headlines, the stock closed higher 17 times and lower 8 times, with a median move of 3.0% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ONCY | SPY |
|---|---|---|---|
| Jun 2, 2026 | Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer | -12.5% | +0.1% |
| Jun 1, 2026 | Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches | +1.9% | +0.3% |
| May 26, 2026 | From Ambrx to Oncolytics: Why Jared Kelly Believes the Market May Be Missing the Bigger Oncology Story | +0.1% | +0.7% |
| May 22, 2026 | Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep's Potential Across Gastrointestinal Tumors | +2.5% | +0.4% |
| May 4, 2026 | Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer | +6.6% | -0.4% |
| Apr 27, 2026 | Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study | -6.0% | +0.2% |
Quantisnow market dataNASDAQ
ONCY
Oncolytics Biotech Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for ONCY
Full ONCY profile on Quantisnow Follow ONCY and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time